Behavioural support and nicotine replacement therapy for smokeless tobacco cessation in Bangladesh, India and Pakistan: A pilot randomized controlled trial.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Smokeless tobacco (ST) use in South Asia is high, yet interventions to support its cessation are lacking.

The researchers tested the feasibility of delivering interventions for ST cessation in South Asia.

Who Took Part

The abstract describes 264 participants taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The researchers used a 2 × 2 factorial design, pilot randomized controlled trial with a duration of 26 weeks, including baseline and follow-up (6, 12 and 26 weeks) assessments.

Participants were randomized to one of three treatment options [8-week support through nicotine replacement therapy (NRT, n = 66), a behavioural intervention for smokeless tobacco cessation in adults (BISCA, n = 66) or their combination (n = 66)] or the control condition of very brief advice (VBA) to quit (n = 66).

How the Study Was Run

The researchers set it up as a randomized and pilot study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

Two primary health-care facilities each in Dhaka (Bangladesh) and Karachi (Pakistan) and a walk-in cancer screening clinic in Noida (India) took part.

Recruitment and retention, data completeness and feasibility of intervention delivery were evaluated.

Biochemically verified abstinence from tobacco, using salivary cotinine, was measured at 26 weeks.

What Was Measured

PubMed files the paper under topics including Bangladesh, India, Pilot Projects, Pakistan, Tobacco Use Cessation, Tobacco Use Cessation Devices and Tobacco, Smokeless.

Author keywords: Behavioural support, South Asia, nicotine replacement, pilot trial, smokeless tobacco and tobacco cessation.

What This Means in Plain Language

The paper is a randomized and pilot study of Therapeutic nicotine (patch, non-peptide) in 264 participants.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Addiction (Abingdon, England)), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.